search
Back to results

Efficacy of Metacognitive Training for Schizophrenia - a Study Protocol

Primary Purpose

Schizophrenia

Status
Completed
Phase
Not Applicable
Locations
Portugal
Study Type
Interventional
Intervention
Metacognitive Training in Schizophrenia (MCT)
Treatment As Usual (TAU)
Sponsored by
University Rovira i Virgili
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional supportive care trial for Schizophrenia focused on measuring schizophrenia, metacognitive training, insight, positive symptoms, functioning

Eligibility Criteria

18 Years - 65 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • age between 18 and 65 years;
  • diagnosis of schizophrenia evaluated by Psychiatrist Assistant;
  • that didn't have any changes in neuroleptics medication four months before program.

Exclusion Criteria:

  • substance dependence;
  • very severe psychotic symptoms that impedes understanding the objectives of the sessions;
  • had changes in neuroleptics medication four months before program.

Sites / Locations

  • Lara Manuela Guedes de Pinho

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Active Comparator

Arm Label

Experimental Group

Control Group

Arm Description

Participants will be randomly allocated to either Metacognitive Training (MCT) (experimental group). In both groups will be maintained the "treatment as usual" (TAU).

The control group will not participate in the MCT program. In both groups will be maintained the TAU.

Outcomes

Primary Outcome Measures

Psychotic Symptom Rating Scales (PSYRATS) - moment 1
This instrument is a structured interview that assesses the detailed measurement of delusions and hallucinations. The PSYRATS have 17 items and two subscales: one subscale assesses delusions (6 items) and the other subscale assess hallucinations (11 items). Each item has a classification of five points (0-4). The total score is the sum of all points. It is was developed by Haddock, McCarron, Tarrier and Faragher in 1999 (validated for the Portuguese population by Telles-Correia et al in 2017).
Psychotic Symptom Rating Scales (PSYRATS) - moment 2
This instrument is a structured interview that assesses the detailed measurement of delusions and hallucinations. The PSYRATS have 17 items and two subscales: one subscale assesses delusions (6 items) and the other subscale assess hallucinations (11 items). Each item has a classification of five points (0-4). The total score is the sum of all points. It is was developed by Haddock, McCarron, Tarrier and Faragher in 1999 (validated for the Portuguese population by Telles-Correia et al in 2017).
Psychotic Symptom Rating Scales (PSYRATS) - moment 3
This instrument is a structured interview that assesses the detailed measurement of delusions and hallucinations. The PSYRATS have 17 items and two subscales: one subscale assesses delusions (6 items) and the other subscale assess hallucinations (11 items). Each item has a classification of five points (0-4). The total score is the sum of all points. It is was developed by Haddock, McCarron, Tarrier and Faragher in 1999 (validated for the Portuguese population by Telles-Correia et al in 2017).
Beck Cognitive Insight Scale (BCIS) - moment 1
This scale has 15 items and it is a self-response questionnaire that was developed by Beck, Baruch, Balter, Steer, & Warman in 2004 and evaluated the consciousness of the illness. The BCIS is comprised of two subscales: self-reflectiveness and self-certainty. The total score for each scale is the sum of the item scores that comprise it (see below). The BCIS composite index is calculated as self-reflectiveness minus self-certainty. Poorer cognitive insight is indexed by lower scores on the self-reflectiveness subscale, higher self-certainty scores, and lower BCIS composite index scores. Step 1. Score every item on the BCIS from "0" to "3" according to the following rule: "Do Not Agree at All" = 0 "Agree Slightly" = 1 "Agree a Lot" = 2 "Agree Completely" = 3 (in process of validation to Portuguese population by investigators of this study)
Beck Cognitive Insight Scale (BCIS) - moment 2
This scale has 15 items and it is a self-response questionnaire that was developed by Beck, Baruch, Balter, Steer, & Warman in 2004 and evaluated the consciousness of the illness. The BCIS is comprised of two subscales: self-reflectiveness and self-certainty. The total score for each scale is the sum of the item scores that comprise it (see below). The BCIS composite index is calculated as self-reflectiveness minus self-certainty. Poorer cognitive insight is indexed by lower scores on the self-reflectiveness subscale, higher self-certainty scores, and lower BCIS composite index scores. Step 1. Score every item on the BCIS from "0" to "3" according to the following rule: "Do Not Agree at All" = 0 "Agree Slightly" = 1 "Agree a Lot" = 2 "Agree Completely" = 3 (in process of validation to Portuguese population by investigators of this study)
Beck Cognitive Insight Scale (BCIS) - moment 3
This scale has 15 items and it is a self-response questionnaire that was developed by Beck, Baruch, Balter, Steer, & Warman in 2004 and evaluated the consciousness of the illness. The BCIS is comprised of two subscales: self-reflectiveness and self-certainty. The total score for each scale is the sum of the item scores that comprise it (see below). The BCIS composite index is calculated as self-reflectiveness minus self-certainty. Poorer cognitive insight is indexed by lower scores on the self-reflectiveness subscale, higher self-certainty scores, and lower BCIS composite index scores. Step 1. Score every item on the BCIS from "0" to "3" according to the following rule: "Do Not Agree at All" = 0 "Agree Slightly" = 1 "Agree a Lot" = 2 "Agree Completely" = 3 (in process of validation to Portuguese population by investigators of this study)
World Health Disability Assessment Schedule (WHODAS 2.0) - moment 1
This instrument evaluated the functionality levels and was developed by WHO. It has 12 items and it is a self-response questionnaire (validated for the Portuguese population by Moreira, Alvarelhão, Silva, Costa and Queirós in 2015).
World Health Disability Assessment Schedule (WHODAS 2.0) - moment 2
This instrument evaluated the functionality levels and was developed by WHO. It has 12 items and it is a self-response questionnaire (validated for the Portuguese population by Moreira, Alvarelhão, Silva, Costa and Queirós in 2015).
World Health Disability Assessment Schedule (WHODAS 2.0) - moment 3
This instrument evaluated the functionality levels and was developed by WHO. It has 12 items and it is a self-response questionnaire (validated for the Portuguese population by Moreira, Alvarelhão, Silva, Costa and Queirós in 2015).
Personal and Social Performance Scale (PSP) - moment 1
this scale was developed by Morosini, Magliano, Brambilla, Ugolini and Pioli in 2000 and it assesses patients' social functioning with four main areas: socially useful activities, personal and social relationships, self-care and disturbing and aggressive behaviours (validated for the Portuguese population by Brissos et al., 2012).
Personal and Social Performance Scale (PSP) - moment 2
this scale was developed by Morosini, Magliano, Brambilla, Ugolini and Pioli in 2000 and it assesses patients' social functioning with four main areas: socially useful activities, personal and social relationships, self-care and disturbing and aggressive behaviours (validated for the Portuguese population by Brissos et al., 2012).
Personal and Social Performance Scale (PSP) - moment 3
this scale was developed by Morosini, Magliano, Brambilla, Ugolini and Pioli in 2000 and it assesses patients' social functioning with four main areas: socially useful activities, personal and social relationships, self-care and disturbing and aggressive behaviours (validated for the Portuguese population by Brissos et al., 2012).

Secondary Outcome Measures

Full Information

First Posted
February 5, 2019
Last Updated
April 4, 2020
Sponsor
University Rovira i Virgili
Collaborators
Center for Health Technology and Services Research
search

1. Study Identification

Unique Protocol Identification Number
NCT03891186
Brief Title
Efficacy of Metacognitive Training for Schizophrenia - a Study Protocol
Official Title
A Randomized Controlled Trial to Evaluate the Efficacy of Metacognitive Training for Schizophrenia Applied by Mental Health Nurses: Study Protocol
Study Type
Interventional

2. Study Status

Record Verification Date
April 2020
Overall Recruitment Status
Completed
Study Start Date
April 15, 2019 (Actual)
Primary Completion Date
April 4, 2020 (Actual)
Study Completion Date
April 4, 2020 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
University Rovira i Virgili
Collaborators
Center for Health Technology and Services Research

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No

5. Study Description

Brief Summary
Metacognitive training (MCT) for schizophrenia has been used in several countries, but its efficacy remains unclear. MCT is a program group that consists of changing the cognitive infrastructure of delusions. This study aims to evaluate the efficacy of the Portuguese version of the metacognitive training programme and its effects on psychotic symptoms, insight to the disorder and functionality
Detailed Description
A randomized controlled trial that will be realized in six psychiatric institutions of Portugal. Pilot study will be carried out initially. The sample will be constituted by individuals diagnosed with schizophrenia (experimental group (n=30) and control group (n=30). The evaluation instruments will be utilized are PSYRATS, BCIS, PSP and WHODAS 2.0 applied to both groups in three different moments. In experimental group the eight MCT modules will be applied over four weeks. The objective is to compare the outcomes associated with "treatment-as-usual" and the benefits of implementing the Metacognitive Training for Schizophrenia. The hypothesis to be validated in this trial are: the schizophrenic patients who integrate the experimental group and participate in the MCT program will reduce the severity of psychotic symptoms and will present a better insight to disease and a better functioning on the final of the program than the control group; in participants that participating in the MCT program, the psychotic symptoms decrease at the end of the program and in the follow up (three months later) and the awareness for the disease and functioning improves.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Schizophrenia
Keywords
schizophrenia, metacognitive training, insight, positive symptoms, functioning

7. Study Design

Primary Purpose
Supportive Care
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Model Description
Metacognitive Training For Schizophrenia
Masking
InvestigatorOutcomes Assessor
Masking Description
Eligible participants will be recruited by the investigators in collaboration with the multidisciplinary team of each institution. A baseline assessment will be carried out and the instruments will be applied after informed consent by participants. Participants will be randomly allocated to either Metacognitive Training (MCT) (experimental group). The control group will not participate in the MCT program. In both groups will be maintained the TAU. The variables for whom the participants are stratified are educational level, duration of mental disorder and type of treatment. All participants will be re-assessed at the end of the program and three months later. The program will be applied during four weeks (two session per week).
Allocation
Randomized
Enrollment
60 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Experimental Group
Arm Type
Experimental
Arm Description
Participants will be randomly allocated to either Metacognitive Training (MCT) (experimental group). In both groups will be maintained the "treatment as usual" (TAU).
Arm Title
Control Group
Arm Type
Active Comparator
Arm Description
The control group will not participate in the MCT program. In both groups will be maintained the TAU.
Intervention Type
Behavioral
Intervention Name(s)
Metacognitive Training in Schizophrenia (MCT)
Intervention Description
MCT is a group program with eight modules referring to common cognitive and biases in solving problems in schizophrenia. The following topics of MCT are: attribution blaming and taking credit (module 1), jumping to conclusions (modules 2 and 7), changing beliefs (module 3), deficits in theory of mind and social cognition (modules 4 and 6), overconfidence in (memory) errors (module 5) and depression and low self-esteem (module 8). Each session lasts 45 to 60 minutes and follows a protocol defined in the manual "Metacognitive Training for Psychosis (MCT)" that is currently available in 35 languages (available in www.uke.de/mkt).
Intervention Type
Other
Intervention Name(s)
Treatment As Usual (TAU)
Intervention Description
In both groups will be maintained the TAU.
Primary Outcome Measure Information:
Title
Psychotic Symptom Rating Scales (PSYRATS) - moment 1
Description
This instrument is a structured interview that assesses the detailed measurement of delusions and hallucinations. The PSYRATS have 17 items and two subscales: one subscale assesses delusions (6 items) and the other subscale assess hallucinations (11 items). Each item has a classification of five points (0-4). The total score is the sum of all points. It is was developed by Haddock, McCarron, Tarrier and Faragher in 1999 (validated for the Portuguese population by Telles-Correia et al in 2017).
Time Frame
PSYRATS will be applied a week before the first session of Metacognitive Training.
Title
Psychotic Symptom Rating Scales (PSYRATS) - moment 2
Description
This instrument is a structured interview that assesses the detailed measurement of delusions and hallucinations. The PSYRATS have 17 items and two subscales: one subscale assesses delusions (6 items) and the other subscale assess hallucinations (11 items). Each item has a classification of five points (0-4). The total score is the sum of all points. It is was developed by Haddock, McCarron, Tarrier and Faragher in 1999 (validated for the Portuguese population by Telles-Correia et al in 2017).
Time Frame
PSYRATS will be applied up to 1 week after eight session, to both groups.
Title
Psychotic Symptom Rating Scales (PSYRATS) - moment 3
Description
This instrument is a structured interview that assesses the detailed measurement of delusions and hallucinations. The PSYRATS have 17 items and two subscales: one subscale assesses delusions (6 items) and the other subscale assess hallucinations (11 items). Each item has a classification of five points (0-4). The total score is the sum of all points. It is was developed by Haddock, McCarron, Tarrier and Faragher in 1999 (validated for the Portuguese population by Telles-Correia et al in 2017).
Time Frame
This instrument will be reapplied to follow up evaluation, up to 3 months after the final program, in both groups.
Title
Beck Cognitive Insight Scale (BCIS) - moment 1
Description
This scale has 15 items and it is a self-response questionnaire that was developed by Beck, Baruch, Balter, Steer, & Warman in 2004 and evaluated the consciousness of the illness. The BCIS is comprised of two subscales: self-reflectiveness and self-certainty. The total score for each scale is the sum of the item scores that comprise it (see below). The BCIS composite index is calculated as self-reflectiveness minus self-certainty. Poorer cognitive insight is indexed by lower scores on the self-reflectiveness subscale, higher self-certainty scores, and lower BCIS composite index scores. Step 1. Score every item on the BCIS from "0" to "3" according to the following rule: "Do Not Agree at All" = 0 "Agree Slightly" = 1 "Agree a Lot" = 2 "Agree Completely" = 3 (in process of validation to Portuguese population by investigators of this study)
Time Frame
BCIS will be applied a week before the first session of Metacognitive Training
Title
Beck Cognitive Insight Scale (BCIS) - moment 2
Description
This scale has 15 items and it is a self-response questionnaire that was developed by Beck, Baruch, Balter, Steer, & Warman in 2004 and evaluated the consciousness of the illness. The BCIS is comprised of two subscales: self-reflectiveness and self-certainty. The total score for each scale is the sum of the item scores that comprise it (see below). The BCIS composite index is calculated as self-reflectiveness minus self-certainty. Poorer cognitive insight is indexed by lower scores on the self-reflectiveness subscale, higher self-certainty scores, and lower BCIS composite index scores. Step 1. Score every item on the BCIS from "0" to "3" according to the following rule: "Do Not Agree at All" = 0 "Agree Slightly" = 1 "Agree a Lot" = 2 "Agree Completely" = 3 (in process of validation to Portuguese population by investigators of this study)
Time Frame
BCIS will be applied up to 1 week after eight session of the MCT, to both groups
Title
Beck Cognitive Insight Scale (BCIS) - moment 3
Description
This scale has 15 items and it is a self-response questionnaire that was developed by Beck, Baruch, Balter, Steer, & Warman in 2004 and evaluated the consciousness of the illness. The BCIS is comprised of two subscales: self-reflectiveness and self-certainty. The total score for each scale is the sum of the item scores that comprise it (see below). The BCIS composite index is calculated as self-reflectiveness minus self-certainty. Poorer cognitive insight is indexed by lower scores on the self-reflectiveness subscale, higher self-certainty scores, and lower BCIS composite index scores. Step 1. Score every item on the BCIS from "0" to "3" according to the following rule: "Do Not Agree at All" = 0 "Agree Slightly" = 1 "Agree a Lot" = 2 "Agree Completely" = 3 (in process of validation to Portuguese population by investigators of this study)
Time Frame
This instrument will be reapplied to follow up evaluation, up to 3 months after the final program in both groups.
Title
World Health Disability Assessment Schedule (WHODAS 2.0) - moment 1
Description
This instrument evaluated the functionality levels and was developed by WHO. It has 12 items and it is a self-response questionnaire (validated for the Portuguese population by Moreira, Alvarelhão, Silva, Costa and Queirós in 2015).
Time Frame
WHODAS 2.0 will be applied a week before the first session of Metacognitive Training
Title
World Health Disability Assessment Schedule (WHODAS 2.0) - moment 2
Description
This instrument evaluated the functionality levels and was developed by WHO. It has 12 items and it is a self-response questionnaire (validated for the Portuguese population by Moreira, Alvarelhão, Silva, Costa and Queirós in 2015).
Time Frame
WHODAS 2.0 will be applied up to 1 week after eight session of the MCT, to both groups
Title
World Health Disability Assessment Schedule (WHODAS 2.0) - moment 3
Description
This instrument evaluated the functionality levels and was developed by WHO. It has 12 items and it is a self-response questionnaire (validated for the Portuguese population by Moreira, Alvarelhão, Silva, Costa and Queirós in 2015).
Time Frame
This instrument will be reapplied to follow up evaluation, up to 3 months after the final program in both groups.
Title
Personal and Social Performance Scale (PSP) - moment 1
Description
this scale was developed by Morosini, Magliano, Brambilla, Ugolini and Pioli in 2000 and it assesses patients' social functioning with four main areas: socially useful activities, personal and social relationships, self-care and disturbing and aggressive behaviours (validated for the Portuguese population by Brissos et al., 2012).
Time Frame
PSP will be applied a week before the first session of Metacognitive Training
Title
Personal and Social Performance Scale (PSP) - moment 2
Description
this scale was developed by Morosini, Magliano, Brambilla, Ugolini and Pioli in 2000 and it assesses patients' social functioning with four main areas: socially useful activities, personal and social relationships, self-care and disturbing and aggressive behaviours (validated for the Portuguese population by Brissos et al., 2012).
Time Frame
PSP will be applied up to 1 week after eight session of the MCT, to both groups
Title
Personal and Social Performance Scale (PSP) - moment 3
Description
this scale was developed by Morosini, Magliano, Brambilla, Ugolini and Pioli in 2000 and it assesses patients' social functioning with four main areas: socially useful activities, personal and social relationships, self-care and disturbing and aggressive behaviours (validated for the Portuguese population by Brissos et al., 2012).
Time Frame
This instrument will be reapplied to follow up evaluation, up to 3 months after the final program in both groups.
Other Pre-specified Outcome Measures:
Title
Sociodemographic and clinical data
Description
Age, gender (male (1) or female (2)), marital status (single (1), married (2), divorced (3), widower (4)), cohabitation (institution (1), alone (2), parents (3), mother or father (4), son (5), sibling (6), other family (7), other non-family (8)), educational level (illiterate (1), primary education (2), 6th grade (3), 9th grade (4), Secondary education (5), Bachelor (6), Master degree (7), PhD (8)), professional/employment status (employee (1), unemployed (2), disability (3), retired (4), medical leave (5)), duration of mental disorder (< 1 year (1), 1 to 2 years (2), 2 to 5 years (3), 5 to 10 years (4), 10 to 20 years (5), > 20 years ago (6)), number of Psychiatric hospitalizations (only once (1), 2 to 5 times (2), 6 to 10 times (3), more than 10 times (4)) and substance use (tobacco (1), alcohol (2), other drugs(3)). This data will be collected a week before be beginning program to all participants.
Time Frame
Sociodemographic and clinical data will be applied a week before the first session of Metacognitive Training on both groups.

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
65 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: age between 18 and 65 years; diagnosis of schizophrenia evaluated by Psychiatrist Assistant; that didn't have any changes in neuroleptics medication four months before program. Exclusion Criteria: substance dependence; very severe psychotic symptoms that impedes understanding the objectives of the sessions; had changes in neuroleptics medication four months before program.
Facility Information:
Facility Name
Lara Manuela Guedes de Pinho
City
Portalegre
ZIP/Postal Code
7300-004
Country
Portugal

12. IPD Sharing Statement

Plan to Share IPD
Undecided
Citations:
PubMed Identifier
33222210
Citation
de Pinho LMG, Sequeira CADC, Sampaio FMC, Rocha NB, Ozaslan Z, Ferre-Grau C. Assessing the efficacy and feasibility of providing metacognitive training for patients with schizophrenia by mental health nurses: A randomized controlled trial. J Adv Nurs. 2021 Feb;77(2):999-1012. doi: 10.1111/jan.14627. Epub 2020 Nov 22.
Results Reference
derived

Learn more about this trial

Efficacy of Metacognitive Training for Schizophrenia - a Study Protocol

We'll reach out to this number within 24 hrs